Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2000-04-26
2002-11-26
Kunz, Gary L. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000, C530S324000
Reexamination Certificate
active
06486122
ABSTRACT:
FIELD OF THE INVENTION
The invention relates generally to transforming growth factor alpha ( ) and more specifically to methods of using TGF-&agr; for stimulating hematopoiesis, for suppressing immune function associated with autoimmune diseases, for suppressing inflammatory responses mediated by excessive histamine release and by expression of TNF-receptors and associated pro-inflammatory cytokines, and for treating cachexia or for treating or preventing mucositis and gastrointestinal-associated disorders.
BACKGROUND
There are several disease treatments that could significantly benefit by having cells regenerate after injury or lesion formation, particularly in the CNS, in the immune system and in the gastrointestinal tract. In some instances, a particular treatment for a disease often detrimentally affects the subject being treated. For example, administration of chemotherapeutic agents to subjects results in destruction of healthy cells, for example, cells of the gastrointestinal tract. A number treatment-related disorders are related to the choice of chemotherapeutic agent. Such agents include carmustine (BCNU), chlorambucil (LEUKERAN), cisplatin (PLATINOL), Cytarabine, doxorubicin (ADRIAMYCIN), fluorouracil (5-FU), methoxetrate (MEXATE), taxol, CPT111, etoposide, and plicamycin (MITHRACIN) which are known for their direct stomatotoxic potential (Sonis, 1993, “Oral Complications in Cancer Therapy,” In: Principles and Practice of Oncology, pp. 2385-2394, DeVitta et al., Eds., J. B. Lippincott, Philadelphia) and hence incidence of mucositis.
Oral mucositis can be initiated by the cytotoxic effects of chemotherapy and/or radiotherapy on the rapidly dividing epithelial cells of the oropharyngeal mucosa, and is exacerbated by infection with both endogenous oral flora and opportunistic bacterial and fungal pathogens. Complications related to oral mucositis vary in the different patient populations affected, but typically include pain, poor oral intake with consequent dehydration and weight loss, and systemic infection with organisms originating in the oral cavity. The pain associated with oral mucositis may be severe requiring narcotic analgesics, and the difficulty in eating can result in patients receiving total parenteral nutrition.
Current therapies have been directed at decreasing oral flora and the extent of infection of oral ulcerations. Systemic treatment with G- and GM-CSF has been shown to result in a decreased incidence of oral mucositis, presumably by allowing for more rapid neutrophil recovery and thus an improved ability to combat infection, although it has been postulated that the CSFs may have a more direct effect on the oral mucosa (Chi et al., 1995, J. Clin. Oncol. 13:2620-2628). In one study, GM-CSF was reported to exacerbate mucositis. (Cartee et al., 1994, Cytokine 7:471-477). Benzydamine hydrochloride, a nonsteroidal drug with analgesic and antimicrobial properties, has been studied both in patients undergoing radiation therapy and in patients receiving intra-arterial chemotherapy.
In addition, diseases associated with epithelial cell depletion in the gastrointestinal tract often increase the risk of related disorders. Such related disorders include infection by opportunistic pathogens as well as weight loss associated with the loss in nutrient uptake in the gastrointestinal tract.
SUMMARY OF THE INVENTION
The present invention is based on the seminal discovery that TGF-&agr; and functionally related polypeptides, TGF-&agr; mimetics, functional TGF-&agr; peptides, and polynucleotides encoding such polypeptides and peptide fragments are effective for treating or preventing weight-loss in subjects having disorders or diseases associated with weight-loss (e.g., cachexia). In addition, the polypeptides of the invention have mitogenic and barrier function (e.g., protective) effects on stem cells and their differentiated progeny from a variety of tissues including the gastrointestinal system, the nervous system and the hematopoietic system.
In a first embodiment, the invention provides a method of treating a subject having or at risk of having cachexia comprising administering to the subject a transforming growth factor-alpha (TGF-&agr;) polypeptide in an amount effective to prevent or reduce weight-loss. In one aspect, the invention provides a method of increasing the body weight of a subject comprising administering to the subject, prior to, simultaneously with, or substantially following chemotherapy, a transforming growth factor-alpha (TGF-&agr;) polypeptide in an amount effective to increase the weight of the subject. In one aspect the subject has AIDS related complex (ARC) or AIDS and cachexia associated with such diseases.
In another embodiment, the invention provides a method for treating or preventing mucositis of the gastrointestinal tract in a subject, comprising administering a TGF&agr; or related polypeptide in an amount effective to treat or prevent mucositis in the subject. For example, a subject undergoing chemotherapy can be treated by the method of the invention.
The invention also provides a polypeptide comprising a peptide having a sequence NH
2
-X
1a
-Cys-His-Ser-X
1b
-X
2
-X
1a
-X
1b
-X
1a
-X
3
-Cys-COOH (SEQ ID NO:4) wherein X
1a
and X
1b
are independently Val, Gly or Ala; X
2
is Tyr or Phe; X
3
is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF-&agr; activity.
In another embodiment, the invention provides a polypeptide comprising a peptide having a sequence NH
2
-X
1a
-Cys-His-Ser-X
1b
-X
2
-X
1a
-X
1b
-X
1a
-X
3
-Cys-COOH (SEQ ID NO:4) wherein X
1a
and X
1b
are independently Val, Gly or Ala; X
2
is Tyr or Phe; X
3
is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF-&agr; activity and wherein at least one or more of the following amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4: -X
4
-His-X
1c
-X
4
-X
5
-X
6
-X
1c
(SEQ ID NO:5) wherein X
4
is Glu or Asp; X
5
is Leu or Ile; and X
6
is Asp or Glu.
In yet another embodiment, the invention provides a pharmaceutical composition comprising a polypeptide having a sequence NH
2
-X
1a
-Cys-His-Ser-X
1b
-X
2
-X
1a
-X
1b
-X
1a
-X
3
-Cys COOH (SEQ ID NO:4) wherein X
1a
and X
1b
are independently Val, Gly or Ala; X
2
is Tyr or Phe; X
3
is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF-&agr; activity, and a pharmaceutically acceptable carrier. In addition, at least one or more of the following amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4: -X
4
-His-X
1c
-X
4
-X
5
-X
6
-X
1c
(SEQ ID NO:5) wherein X
4
is Glu or Asp; X
5
is Leu or Ile; and X
6
is Asp or Glu.
The invention also provides a compound that acts as a TGF-&agr; mimetic, comprising a compound of formula: loop peptide N-terminus-linker-cyclic C
4
H
8
N
2
-linker-loop peptide N-terminus wherein the linker moiety is designed to link the N-terminus of the loop peptide to a nitrogen atom of the ring C
4
H
8
N
2
and wherein the loop peptide has a sequence NH
2
-X
1a
-Cys-His-Ser-X
1b
-X
2
-X
1a
-X
1b
-X
1a
-X
3
-Cys COOH (SEQ ID NO:4) wherein X
1a
and X
1b
are independently Val, Gly or Ala; X
2
is Tyr or Phe; X
3
is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF-&agr; activity.
REFERENCES:
patent: 4749683 (1988-06-01), Murphy et al.
patent: 4816561 (1989-03-01), Todaro
patent: 4863899 (1989-09-01), Todaro
patent: 5240912 (1993-08-01), Todaro
patent: 5633147 (1997-05-01), Meissner et al.
patent: 5814308 (1998-09-01), Zhang
patent: 5851832 (1998-12-01), Weiss et al.
patent: 5980885 (1999-11-01), Weiss et al.
patent: 0 190 018 (1986-01-01), None
patent: WO 91/01141 (1991-02-01), None
patent: WO 97/25349 (1997-07-01), None
patent: WO 98/24468 (1998-06-01), None
Nestor et al., “A Synthetic Fragment of Rat Transforming Growth Factor &agr; With Receptor Bindi
Felker Thomas S.
Paskell Stefan
Twardzik Daniel R.
Gray Cary Ware & Friedenrich LLP
Haile Lisa A.
Kunz Gary L.
Landsman Robert S.
Reynolds Kelly K.
LandOfFree
Methods of increasing body weight in a subject by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of increasing body weight in a subject by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of increasing body weight in a subject by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2930466